Related Experiment Videos
[Carpentier's supra-annular bioprosthesis in aortic position: a mid-term evaluation]
G Fournial1, A Laghzaoui, D Roux
1Service de chirurgie cardio-vasculaire B, CHU-Rangueil, Toulouse.
Archives Des Maladies Du Coeur Et Des Vaisseaux
|December 1, 1995
Summary
The Carpentier-Edwards supra-annular (CESA) bioprosthesis shows favorable medium-term results for aortic valve replacement. It is a suitable choice for patients over 70, with no reoperations needed due to valve issues in this group.
Area of Science:
- Cardiovascular Surgery
- Bioprosthetic Heart Valves
- Geriatric Cardiology
Context:
- Aortic valve replacement is a common procedure for elderly patients.
- Evaluating the long-term durability and safety of bioprosthetic valves is crucial.
- The Carpentier-Edwards supra-annular (CESA) bioprosthesis is a specific type of prosthetic valve used in aortic valve replacement.
Purpose:
- To assess the medium and long-term clinical outcomes of the Carpentier-Edwards supra-annular (CESA 2650) bioprosthesis.
- To evaluate complications such as thromboembolism, structural deterioration, and reoperation rates.
- To determine the suitability of the CESA bioprosthesis in elderly patients (over 70 years).
Summary:
- 160 patients (mean age 71.6 years) underwent aortic valve replacement with the CESA bioprosthesis between 1984 and 1993.
- Follow-up averaged 60 months (749 patient-years), with 96% completeness.
- Actuarial 5- and 10-year survival rates were 78.6% and 59.1%, respectively. Key complication rates included thromboembolism (1.3%/year), structural deterioration (1.5%/year), and reoperation (0.75%/year).
Impact:
- The CESA bioprosthesis demonstrates comparable medium-term results to first-generation porcine valves.
- Low rates of structural deterioration and reoperation were observed, particularly in patients over 70.
- The findings suggest the CESA bioprosthesis may be the preferred option for aortic valve replacement in patients aged 70 and above.